Swedish biotech startup Cellcolabs has secured $12 million in primary funding from Titian Capital’s life sciences platform, bringing its total raised to $37 million.
The investment will accelerate the company’s technical development and international expansion as it builds the global infrastructure for scalable stem cell manufacturing.
Founded in 2021, Cellcolabs specializes in the industrial-scale production of GMP-certified mesenchymal stem cells (MSCs) — widely recognized for their potential in regenerative medicine and immune modulation. The company’s production process is based on a protocol developed over two decades at the Karolinska Institutet, one of the world’s leading medical research universities.
“The industry is reaching an inflection point,” said Dr. Mattias Bernow, CEO of Cellcolabs. “Scientific evidence is mounting, regulatory pathways are opening, and the demand for stem cells has never been greater. Yet scalable access remains the missing piece. Our partnership with Titian Life Sciences gives us both the capital and the global footprint to change that — not someday, but in our lifetime.”
Advertisement
Building the Backbone for Global Stem Cell Supply
Cellcolabs operates a GMP-certified production facility in Stockholm, enabling the large-scale manufacturing of allogeneic MSCs for research and clinical applications. Its platform supports academic and commercial partners — from preclinical research to late-stage clinical trials — and supplies MSCs to university hospitals, biotech firms, and private clients, including professional athletes.
While Cellcolabs itself does not offer direct patient treatments, a subsidiary sponsors international research programs using its stem cells in key therapeutic areas such as cardiovascular prevention, musculoskeletal repair, and age-related frailty.
Lowering the Cost Barrier to Regenerative Medicine
The company’s long-term mission is to reduce the cost of mesenchymal stem cells by up to 90% by 2035, making advanced cell-based therapies accessible to researchers and patients worldwide.
The company’s model is rooted in industrial efficiency, scientific rigor, and ethical transparency — setting new standards for the global stem cell supply chain.
“By combining Sweden’s scientific excellence with industrial scalability, we’re creating a foundation for the next wave of regenerative medicine,” added Bernow.
About Cellcolabs
Cellcolabs is a Stockholm-based biotech impact company revolutionizing access to high-quality stem cells through industrial-scale, GMP-certified production. Spun out of research from the Karolinska Institutet, Cellcolabs partners with leading institutions and biotech firms to power clinical innovation in regenerative medicine, immune modulation, and preventative health. Its mission: to make the life-changing potential of stem cell therapies accessible, affordable, and globally scalable.
